# A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

> **NCT00880321** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 170 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** GSK2118436
- **DRUG:** GSK2118436
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT00880321
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-04
- **Primary completion:** 2011-03-25
- **Final completion:** 2012-03-20
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00880321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00880321, "A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00880321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*